Nuvalent Stock Performance
| NUVL Stock | USD 80.20 0.48 0.59% |
Nuvalent has a performance score of 5 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.16, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nuvalent will likely underperform. Nuvalent right now secures a risk of 2.74%. Please verify Nuvalent downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Nuvalent will be following its current price movements.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nuvalent are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Nuvalent may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return (2.16) | Five Day Return (6.72) | Year To Date Return 0.86 | Ten Year Return 330.29 | All Time Return 330.29 |
1 | Disposition of 601 shares by James Porter of Nuvalent at 76.69 subject to Rule 16b-3 | 04/28/2025 |
2 | Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results | 05/08/2025 |
3 | Disposition of 27000 shares by James Porter of Nuvalent at 27.85 subject to Rule 16b-3 | 05/15/2025 |
4 | Disposition of 100 shares by Henry Pelish of Nuvalent at 29.33 subject to Rule 16b-3 | 06/06/2025 |
5 | Acquisition by James Porter of 27000 shares of Nuvalent at 27.85 subject to Rule 16b-3 | 06/11/2025 |
6 | Acquisition by Darlene Noci of 21985 shares of Nuvalent at 1.08 subject to Rule 16b-3 | 06/12/2025 |
7 | Nuvalent, Inc. Insider Sells 15,964.00 in Stock | 06/13/2025 |
8 | Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | 06/24/2025 |
9 | Nuvalent Receives Raised Price Target from Baird NUVL Stock News | 06/25/2025 |
10 | Disposition of 306 shares by Darlene Noci of Nuvalent at 79.15 subject to Rule 16b-3 | 06/26/2025 |
11 | Disposition of 200 shares by Henry Pelish of Nuvalent at 81.9 subject to Rule 16b-3 | 07/09/2025 |
12 | Disposition of 182 shares by Henry Pelish of Nuvalent at 18.93 subject to Rule 16b-3 | 07/10/2025 |
13 | Disposition of 104 shares by James Porter of Nuvalent at 84.53 subject to Rule 16b-3 | 07/15/2025 |
14 | Disposition of 14700 shares by Balcom Alexandra of Nuvalent at 85.1 subject to Rule 16b-3 | 07/16/2025 |
15 | Nuvalent Begins Phase 3 Trial for ALK-Positive Lung Cancer Drug NUVL Stock News | 07/21/2025 |
| Begin Period Cash Flow | 335.4 M | |
| Total Cashflows From Investing Activities | -573.5 M |
Nuvalent Relative Risk vs. Return Landscape
If you would invest 7,398 in Nuvalent on April 24, 2025 and sell it today you would earn a total of 670.00 from holding Nuvalent or generate 9.06% return on investment over 90 days. Nuvalent is currently generating 0.1793% in daily expected returns and assumes 2.7399% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Nuvalent, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nuvalent Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nuvalent's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nuvalent, and traders can use it to determine the average amount a Nuvalent's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0654
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NUVL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.74 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Nuvalent is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nuvalent by adding it to a well-diversified portfolio.
Nuvalent Fundamentals Growth
Nuvalent Stock prices reflect investors' perceptions of the future prospects and financial health of Nuvalent, and Nuvalent fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nuvalent Stock performance.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 4.85 B | ||||
| Shares Outstanding | 66.37 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 5.86 X | ||||
| EBITDA | (280.37 M) | ||||
| Net Income | (260.76 M) | ||||
| Cash And Equivalents | 256.96 M | ||||
| Cash Per Share | 5.31 X | ||||
| Total Debt | 71.96 M | ||||
| Debt To Equity | 2.81 % | ||||
| Current Ratio | 25.79 X | ||||
| Book Value Per Share | 14.09 X | ||||
| Cash Flow From Operations | (185.06 M) | ||||
| Earnings Per Share | (4.42) X | ||||
| Market Capitalization | 5.79 B | ||||
| Total Asset | 1.14 B | ||||
| Retained Earnings | (547.05 M) | ||||
| Working Capital | 1.08 B | ||||
| Current Liabilities | 5.46 M | ||||
About Nuvalent Performance
By examining Nuvalent's fundamental ratios, stakeholders can obtain critical insights into Nuvalent's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Nuvalent is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.26) | (0.24) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.24) | (0.23) |
Things to note about Nuvalent performance evaluation
Checking the ongoing alerts about Nuvalent for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nuvalent help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (260.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nuvalent currently holds about 256.96 M in cash with (185.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.31. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Nuvalent Begins Phase 3 Trial for ALK-Positive Lung Cancer Drug NUVL Stock News |
- Analyzing Nuvalent's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nuvalent's stock is overvalued or undervalued compared to its peers.
- Examining Nuvalent's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nuvalent's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nuvalent's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nuvalent's stock. These opinions can provide insight into Nuvalent's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. If investors know Nuvalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Nuvalent is measured differently than its book value, which is the value of Nuvalent that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvalent's value that differs from its market value or its book value, called intrinsic value, which is Nuvalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvalent's market value can be influenced by many factors that don't directly affect Nuvalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.